Showing results (61-70 of 715) with videos related to
Sort By:
Pageof 72
American Journal of Hematology|November 6, 2018
Treatment-free remission with first- and second-generation tyrosine kinase inhibitorsJorge Cortes, Delphine Rea, Jeffrey H LiptonFuture Oncology (London, England)|December 13, 2006
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinibAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge CortesExpert Opinion on Drug Safety|April 9, 2013
Cardiovascular toxicity of tyrosine kinase inhibitorsElie Mouhayar, Jean-Bernard Durand, Jorge CortesClinical Lymphoma, Myeloma & Leukemia|June 25, 2013
Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approvalHagop M Kantarjian, Susan O'Brien, Jorge CortesNature Reviews. Clinical Oncology|August 5, 2009
Imatinib and beyond--exploring the full potential of targeted therapy for CMLAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge CortesJournal of the National Comprehensive Cancer Network : JNCCN|October 12, 2012
Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cureJorge Cortes, John M Goldman, Timothy HughesExpert Review of Anticancer Therapy|April 2, 2004
Novel therapies for patients with chronic myeloid leukemiaFrancis J Giles, Hagop Kantarjian, Jorge CortesClinical Lymphoma, Myeloma & Leukemia|May 29, 2012
Nilotinib-associated vascular eventsAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge CortesClinical Case Reports|August 28, 2018
Acute respiratory syndrome following accidental inhalation of mercury vaporJorge Cortes, Jaime Peralta, Rienzi Díaz-NavarroCancer|September 10, 2009
Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge CortesPageof 72